Rani Therapeutics Appoints Michelle Gilson to Board of Directors

Management
โดย GlobeNewswire·Read original
Summary · why it matters

Rani Therapeutics has appointed Michelle Gilson, former Chief Financial Officer of Arcellx, to its Board of Directors, where she will serve as Chair of the Audit Committee. Gilson brings deep capital markets and biotech financial leadership experience, having played a central role in Arcellx’s financial strategy and its acquisition by Gilead in 2026. Her background also includes biotechnology equity research analyst roles at Canaccord Genuity, Jefferies, Nomura, Oppenheimer & Co., and Goldman Sachs. Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery of biologics using its RaniPill capsule technology.

Impact on stocks 8

Financials▲ · 4 stocks
Biotech & Genomic Medicine▲ · 2 stocks
Industrials▲ · 2 stocks

Off-coverage companies 1

Canaccord Genuity Group Inc.Private± Mixed
relevance

© 2026 MarketDXNews